$0.64 -0.01 (%) ImmunoCellular Therapeutics Ltd - AMEX

Nov. 21, 2014 | 03:59 PM

Partner Headlines

  1. US Stock Futures Up Ahead Of New Home Sales Report

    Benzinga | Sep. 24, 2014 | 07:20AM EST
  2. 5 Companies Developing New Cancer Drugs

    Benzinga | Aug. 19, 2014 | 13:20PM EST
  3. Morning Movers for Feb. 25, 2014: IMUC, MSO, ZU, CARA, VSI, TSLA, XOMA, BCRX Moving Higher, RP, ODP, VVUS, AINV, MGIC, ALSN Lower

    Benzinga | Feb. 25, 2014 | 09:41AM EST
  4. Morning Market Losers

    Benzinga | Jan. 22, 2014 | 10:29AM EST
  5. Morning Market Movers

    Benzinga | Jan. 21, 2014 | 10:30AM EST
  6. Morning Market Losers

    Benzinga | Dec. 12, 2013 | 09:59AM EST
  7. UPDATE: MLV & Co. Downgrades ImmunoCellular Therapeutics on Negative Outlook for ICT-107

    Benzinga | Dec. 12, 2013 | 08:58AM EST
  8. ImmunoCellular Therapeutics Announces Positive ICT-107 Phase II Study Results

    Benzinga | Dec. 11, 2013 | 16:02PM EST
  9. ImmunoCellular Therapeutics Expands Manufacturing Relationship with Neostem's Progenitor Cell Therapy

    Benzinga | Dec. 3, 2013 | 06:03AM EST
  10. Benzinga's Top Initiations

    Benzinga | Aug. 29, 2013 | 09:04AM EST
  11. ImmunoCellular Therapeutics Appoints Anthony J. Gringeri, PhD, as Senior Vice President, Strategic Resources

    Benzinga | Aug. 28, 2013 | 16:00PM EST
  12. ImmunoCellular Therapeutics Announces Pricing of its Previously Announced Public Offering of Common Stock and Warrants

    Benzinga | Oct. 18, 2012 | 03:12AM EST
  13. VirnetX Holding Corporation, ImmunoCellular Therapeutics Gapping Down Tuesday

    FoxBusiness | Aug. 21, 2012 | 04:30AM EST
  14. US Stock Futures Up; Euro Rises Against Dollar

    Benzinga | Aug. 21, 2012 | 00:32AM EST
  15. Stocks To Watch For August 21, 2012

    Benzinga | Aug. 20, 2012 | 18:06PM EST
  16. ImmunoCellular Says CEO Manish Resigned; Yu Named Interim CEO

    Benzinga | Aug. 20, 2012 | 10:04AM EST
  17. A Peek Into The Market Before The Trading Starts

    Benzinga | Aug. 8, 2012 | 01:19AM EST
  18. ImmunoCellular Provides Update on Phase II Clinical Trial of ICT-107 for Treatment of Glioblastoma

    Benzinga | Jul. 2, 2012 | 03:46AM EST
  19. MLV & Co Reiterates Buy, $4.50 PT on ImmunoCellular Therapeutics on Move to NYSE

    Benzinga | May. 25, 2012 | 06:20AM EST
Trading Center